GenomeDx develops and commercializes genomic tests for urologic cancers. Its proprietary Decipher GRID platform is a clinically annotated genomic expression database, and its flagship product predicts the probability of prostate cancer metastasis after surgery by measuring expression levels of 22 biomarkers. Founded in 2008 in San Diego, United States, the company has raised $69.7M in Series C funding from investors including Merck Global Health Innovation Fund and Baird Capital. Founded in 2008, headquartered in San Diego, United States. The team comprises 159 (Dec 31, 2. The company operates in Life Sciences > Genomics, Life Sciences > Oncology, Life Sciences > Clinical Genomics, Life Scien.
← All startups
GenomeDx Biosciences
Series CGenomeDx develops and commercializes genomic tests for urologic cancers. Its proprietary Decipher GRID platform is a clinically annotated genomic expression database, and its flagship product predicts the probability of prostate cancer metastasis after surgery by measuring expression levels of 22 biomarkers. Founded in 2008 in San Diego, United States, the company has raised $69.7M in Series C funding from investors…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Prostate Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Hybridization-based > Microarrays,
Life Sciences Platforms and Tools > Research Assays > Drug Discovery > Microarrays
Institutional investors
CalibriumCD-VentureBaird CapitalMerck Global Health Innovation FundCRGWUTIF CapitalTekla Capital ManagementEMBL Ventures
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.
Similar startups
Raising like GenomeDx Biosciences?
Analyze your pitch deck before your next raise.
Analyze My Deck →